MedTrace Logo

Sphenopalatine Block vs Dexmedetomidine Infusion in Trans Nasal Endoscopic Pituitary Surgery

NCT06639659 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2026-01-02

No results posted yet for this study

Summary

Improving pain and surgical field by using sphenopalatine ganglion block and dexmedetomidine in trans-nasal endoscopic pituitary surgery.

Conditions

  • Sphenopalatine Ganglion Nerve Block
  • Transnasal Endoscopic Pitutary Surgery

Interventions

PROCEDURE

Sphenopalatine Ganglion Block

patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.

DRUG

Dexmedetomidine

patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.

OTHER

General Anesthesia (control group)

patients will be operated under general anesthesia including routine protocol for these cases

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06639659 on ClinicalTrials.gov